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Abstract
Background/Aims: Anemia is common in patients with ad-
vanced chronic kidney disease (CKD). A proportion of pa-
tients present with macrocytic anemia, manifested by ele-
vated mean corpuscular volume (MCV), which has been as-
sociated with worse outcomes in CKD patients. However, it 
is unknown whether elevated MCV is associated with higher 
mortality risk in incident hemodialysis (HD) patients. Meth-
ods: This retrospective observational cohort study examined 
all-cause, cardiovascular, and infectious mortality associa-
tions with both baseline and time-varying MCV in 109,501 
incident HD patients using Cox proportional hazards models 
with 3 levels of hierarchical multivariable adjustment. Odds 
ratios of high versus low baseline MCV were evaluated using 
logistic regression. Results: The mean age of patients was 
65 ± 15 (standard deviation) years and the cohort was 44% 
female, 58% diabetic, and 31% African American. Higher 
MCV was associated with older age, female sex, non-Hispan-
ic White race-ethnicity, alcohol consumption, and having a 
decreased albumin or protein intake. Patients with higher 
MCV levels (> 98 fL) had a higher all-cause, cardiovascular, 
and infectious mortality risk in both baseline and time vary-
ing models, and across all levels of adjustment. In the fully 
adjusted models, compared to a reference of MCV 92–< 94 
fL, patients with a baseline MCV > 100+ fL had a 28% higher 
risk of all-cause mortality (hazard ratio [HR] 1.28, 95% CI 
1.22–1.34), 27% higher risk of cardiovascular mortality (HR 
1.27, 95% CI 1.18–1.36), and 18% higher risk of infectious 
mortality (HR 1.18, 95% CI 1.02–1.38). Associations of higher 
MCV with these adverse outcomes persisted across all exam-
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ined subgroups of clinical characteristics. Conclusions: 
Higher MCV was associated with higher all-cause, cardiovas-
cular, and infectious mortality in HD patients. Further inves-
tigation is necessary to understand the underlying nature of 
the observed association. © 2019 S. Karger AG, Basel
Introduction
Anemia is common in patients with advanced chronic 
kidney disease (CKD) with a prevalence of about 53% in 
CKD stage 5 [1]. Erythrocyte size in anemia can be differ-
entially diagnosed into microcytic, normocytic, or macro-
cytic anemia by the index of mean corpuscular volume 
(MCV) [2]. Anemia in CKD patients is usually normocyt-
ic and normochromic [3], characterized by reduced eryth-
ropoietin production [4], and is associated with reduced 
red blood cell (RBC) survival [5]. Some patients with ad-
vanced CKD present with macrocytosis [3]. Elevated MCV 
(generally 100+ fL; macrocytic anemia) is often character-
istic of underlying conditions such as nutritional deficien-
cies, drug use, or primary bone marrow disorders [2, 6–8], 
and has been associated with worse outcomes in patients 
with acute decompensated heart failure [9] and patients 
undergoing coronary intervention [10]. 
In a recent study investigating a small cohort of 1,439 
Taiwanese patients with stages 3–5 CKD, Hsieh et al. [11], 
found that over a median of 1.9 years of follow-up, pa-
tients with higher MCV (defined as greater than the me-
dian value of 90.8 fL) had a higher risk of all-cause, car-
diovascular, and infection-related mortality, compared to 
patients with MCV levels below the median. Additional-
ly, an earlier prospective, single-center study including 
150 prevalent Canadian dialysis patients found an asso-
ciation between higher MCV (defined as > 102 fL) and 
mortality over 9 months of follow-up [12]. However, 
whether higher MCV is associated with mortality in inci-
dent hemodialysis (HD) patients is still unknown. We hy-
pothesized that in a large nationally representative cohort 
of incident HD patients in the United States, higher MCV 
levels would be associated with a higher risk of mortality. 
Methods
Study Population and Data Source
We examined the data from a total of 208,820 patients with end 
stage renal disease (ESRD) who initiated dialysis therapy from Jan-
uary 1, 2007 to December 31, 2011 within a large dialysis care or-
ganization in the United States. This cohort has been previously 
described [13]. We excluded 46,156 patients who had < 60 days of 
total treatment during their total follow-up time, 29,502 for receiv-
ing treatment with a modality other than in-center HD, 21,145 for 
not having treatment data in the first patient quarter (91 days from 
patient first dialysis date), and 2,516 for not having MCV data in 
the first patient quarter. The final analytical cohort consisted of 
109,501 incident HD patients (online suppl. Fig. S1; for all online 
suppl. material, see www.karger.com/doi/10.1159/000495726). 
Additionally, we created 3 subcohorts for sensitivity analysis 
where we further restricted the analytical cohort based on the 
availability of the covariate of interest: (i) we excluded 100,208 in-
cident HD patients for missing folate in the first patient quarter, 
which led to a subcohort of 9,293 patients with averaged MCV and 
folate measurements in the first patient quarter, (ii) for the second 
subcohort, 98,810 incident HD patients were excluded for missing 
vitamin B12 (B12) measurements in the first patient quarter, 
which resulted in a total of 12,691 patients with MCV and B12 
measurements in the first patient quarter, and finally (iii) 73,167 
patients were excluded for missing residual renal urea clearance 
(KRU) values in the first patient quarter, and therefore, the third 
subcohort consisted of 36,334 incident HD patients.
All data were obtained from electronic records of the dialysis 
organization. ICD-9 codes listed in patient electronic medical re-
cords were used to determine the following conditions: alcohol 
abuse, arteriosclerotic heart disease (ASHD), cerebrovascular dis-
ease, congestive heart failure (CHF), chronic obstructive pulmo-
nary disease (COPD), diabetes mellitus, dyslipidemia, history of 
cancer, hypertension, liver disease, human immunodeficiency vi-
rus (HIV), other cardiovascular disease, and substance abuse. 
Blood samples were drawn using standardized techniques in all 
dialysis clinics and were transported to a central laboratory in De-
land, Florida, typically within 24 hours. All laboratory values were 
measured using automated and standardized methods. Serum cre-
atinine, phosphorus, calcium, albumin, bicarbonate, total iron-
binding capacity (TIBC), and red cell distribution width were mea-
sured monthly. Serum intact parathyroid hormone (iPTH) and 
ferritin were measured at least quarterly. Hemoglobin was mea-
sured weekly to biweekly in most patients. Delivered dialysis dose 
was estimated by single-pool Kt/V (spKt/V) using the urea kinetic 
model [14]. Body mass index (BMI) was calculated as post-HD 
session body weight in kilograms divided by height in meters 
squared. MCV was routinely reported in femtoliters (fL, or 10–15 
L), along with complete blood cell count, and was calculated by 
dividing the Hematocrit  by the RBC count as follows: MCV (fL) = 
(Hematocrit [%]/RBC [in million per μL]). 
To minimize variability, variables with repeated measures 
within each 3-month period (91-day intervals) were averaged to 
obtain a single quarterly mean value. Measurements taken during 
the first 91 days on dialysis therapy, referred to as the “first patient 
quarter,” were used as baseline values.
The study was approved by the institutional review committees 
of the University of California, Irvine, and it was exempted from 
obtaining informed written consent from the patients due to its 
nonintrusive nature and also because patients wanted to remain 
anonymous.
Exposure and Outcome Ascertainment
MCV was the primary exposure of interest. All-cause, cardio-
vascular, and infectious mortality were examined as the primary 
and secondary outcomes, respectively. For the definition of cardio-
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vascular and infectious mortality, please refer to online supple-
mentary Table S1a and b. Patients were divided into 9 groups of 
MCV spaced into equal intervals of 2 fL: < 86, 86–< 88, 88–< 90, 
90–< 92, 92–< 94 (reference), 94–< 96, 96–< 98, 98–< 100, and 100+. 
Associations of MCV with mortality outcomes were examined in 
both baseline and time-varying models. Patients were followed 
from the first date of HD treatment until the patients were censored 
through one of the following events: death, kidney transplantation, 
transfer to another dialysis provider, or end of the study period. 
Statistical Analyses
Baseline patient characteristics were summarized across base-
line MCV groups using proportions, mean (± standard deviation 
[SD]) for parametric variables, or median (interquartile range) for 
non-parametric variables, and were compared using tests-for-
trend. Odds ratios (OR) for high (MCV ≥93 fL) vs. low (MCV < 93 
fL) baseline MCV were calculated using logistic regression. Linear 
regression and correlation coefficients (Spearman or Pearson as 
appropriate) were also calculated to evaluate serum laboratory val-
ues and medication dosage associations with baseline MCV. 
To illustrate trajectories of quarterly averaged MCV across 20 
patient quarters, we used a mixed-effects regression model and 
stratified trajectories by the baseline MCV groups, baseline me-
dian weekly erythropoiesis stimulating agent (ESA) dose groups, 
or baseline cumulative monthly intravenous (IV) iron dose groups. 
The cut points for the median weekly ESA dose groups and cumu-
lative monthly IV iron dose groups were data derived. We further 
performed time-varying adjustment for weekly median ESA dose 
and cumulative monthly IV iron dose in the MCV baseline strati-
fied model, weekly median ESA dose in the baseline ESA stratified 
model, and monthly cumulative IV iron dose in the baseline IV 
iron stratified model.
Associations of MCV with all-cause, cardiovascular, and infec-
tious mortality outcomes were estimated using Cox proportional 
hazards models for both baseline and time-varying models. The 
proportionality assumption was checked using plots of log (–log 
[survival rate]) against log (survival time). We additionally ex-
plored potentially non-linear relationships between MCV and 
mortality outcomes using restricted cubic spline models with 4 
knots placed at the 5th, 35th, 65th, and 95th percentile values of 
MCV. Mortality associations of high vs. low MCV were also exam-
ined across a priori selected subgroups in fully adjusted models, 
and were tested for interactions using the Wald test. In sensitivity 
analyses, we used competing risk regression to further explore the 
association between MCV and cardiovascular and infectious mor-
tality, with cardiovascular or infectious death as the event of inter-
est and non-cardiovascular or non-infectious mortality as the 
competing event, respectively.
All models were examined across 3 levels of hierarchical mul-
tivariable adjustment. The first level was unadjusted and included 
only MCV as the exposure. The second level was case-mix adjust-
ed, which additionally included demographic data (age and sex), 
race-ethnicity (non-Hispanic White, African American, Hispanic, 
Asian, and other), comorbid conditions (alcoholism, ASHD, cere-
brovascular disease, CHF, COPD, diabetes mellitus, dyslipidemia, 
history of cancer, hypertension, liver disease, other cardiovascular 
disease, and substance abuse), insurance type (Medicare, Medic-
aid, other), HD access type (central venous catheter, arteriovenous 
fistula, arteriovenous graft, unkown, other), and spKt/V. The third 
level (fully adjusted model) added markers of the malnutrition-
inflammation complex syndrome (MICS), for which we used 17 
surrogates of nutritional and inflammatory status: hemoglobin, al-
bumin, calcium, phosphorus, iPTH, iron saturation, TIBC, ferri-
tin, bicarbonate, white blood cell count, lymphocyte percentage, 
creatinine, alkaline phosphatase (ALP), BMI, normalized protein 
catabolic rate (nPCR), cumulative monthly IV iron dose per quar-
ter, and ESA quarterly median dose per week. 
In logistic regression analyses, models were restricted to patients 
that had the risk factor of interest, and were adjusted for all other 
components in the fully adjusted model minus the exposure. In 
time-varying models, MCV, access type, laboratory values, and 
medication use were time-updated. In additional analyses, we ad-
justed for (i) folate, (ii) B12, and (iii) KRU individually, in order to 
evaluate potential confounding by these covariates in models re-
stricted to patients with available data on these variables in the first 
patient quarter.
For most covariates (including laboratory markers), baseline 
data were < 1% missing for the total cohort. Folate, B12, and KRU 
were missing at 92, 88, and 67%, respectively, and therefore were 
only included in sensitivity analyses. In time-varying analyses, 
MCV values were carried forward until subsequent updated values 
were reported. Missing values were handled by imputation by me-
dian for quantitative variables, or by creation of a missing catego-
ry for categorical data. All analyses were implemented using Stata, 
version 13.1 (Stata Corporation, College Station, TX, USA).
Results
Study Population
The analytical cohort included 109,501 HD patients 
and total cohort median (interquartile range) follow-up 
time was 494 (230–922) days. Baseline characteristics 
stratified by the 9 MCV categories are shown in Table 1. 
Mean ± SD age of the cohort was 63 ± 15 years. The cohort 
was comprised of 44% females, 58% diabetic patients, and 
31% African American patients. 
At baseline, patients with higher MCV were more likely 
to be female, older, non-diabetic, non-Hispanic White, on 
Medicare, and have comorbidities of alcoholism, COPD, 
history of cancer, and liver disease. Patients with lower 
MCV were more likely to have comorbidities of CHF and 
hypertension. At higher levels of MCV, calcium, ferritin, 
folate, serum iron, iron saturation, and spKt/V increased 
while albumin, creatinine, iPTH, KRU, lymphocyte, phos-
phorous, and total iron binding capacity decreased. Pa-
tients with higher levels of MCV were also more likely to 
receive lower doses of IV iron.
Predictors of Higher MCV
Odds ratios of having MCV levels above the median 
(≥93 fL) in 109,501 HD patients are shown in Table 2 for 
unadjusted, case-mix adjusted, and fully adjusted (case-
mix plus MICS adjusted) models. In fully adjusted mod-
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els, odds of higher baseline MCV were associated with 
older age, female sex, alcohol consumption, COPD, and 
higher ALP. Conversely, being diabetic, being not of non-
Hispanic White race-ethnicity (in particular African 
American race-ethnicity), having higher albumin, or hav-
ing higher nPCR, was associated with lower likelihood of 
having a baseline MCV above the median. 
Linear regression analysis and correlations showed 
similar results (online suppl. Table S2). MCV had positive 
correlations with values for ALP, B12, calcium, ferritin, 
folate, hemoglobin, serum iron, iron saturation, and 
spKt/V. It had negative correlations with albumin, cre-
atinine, iPTH, KRU, lymphocyte, nPCR, phosphorous, 
red cell distribution width, total iron binding capacity, 
white blood cell count, and IV iron. However, the correla-
tions between MCV and various laboratory variables 
were very weak. The strongest correlation was found be-
tween MCV and iron saturation. With every percent in-
crease in iron saturation, MCV increased by 0.15 fL (cor-
relation coefficient and p value, 0.23 and < 0.001).
MCV Trajectories over 20 Patient Quarters
Overall, patients showed a gradual increasing trend to-
ward higher MCV levels over 20 patient quarters. The 
hierarchical order of the baseline MCV groups was main-
tained, and the differences between groups remained rel-
atively constant (online suppl. Fig. S2a). Adjustment for 
time-varying cumulative IV iron dose and median ESA 
dose did not substantially change the course of the trajec-
tory (online suppl. Fig. S2b). Additionally, after stratify-
ing patients according to their baseline ESA dose into 4 
groups, MCV increased during 20 patient quarters and 
showed very little variance across ESA strata (online sup-
pl. Fig. S2c). The trajectory remained consistent after ad-
justing for patient quarter median weekly ESA dose (on-
line suppl. Fig. S2d). Likewise, we stratified patients into 
4 strata for baseline cumulative monthly IV iron dose, 
and found no significant difference in mean MCV levels 
across iron strata over the course of 20 patient quarters 
(online suppl. Fig. S2e), which was not altered after ad-
justment for time-varying monthly cumulative IV iron 
dose (online suppl. Fig. S2f).
All-Cause Mortality
All-cause mortality rates increased linearly across the 
9 groups of MCV and more than doubled from the group 
with the lowest MCV (< 86 fL) to the group with the high-
est MCV (≥100 fL; 117 deaths versus 250 deaths per 1,000 
person-years, online suppl. Table S3). In baseline unad-
justed hazard ratio (HR) models, MCV was linearly as-
sociated with mortality risk (Fig. 1a), where patients with 
MCV ≥100 fL had a 65% higher risk of mortality com-
pared to the referent (HR 1.65, 95% CI 1.58–1.72). After 
case-mix or case-mix plus MICS covariate adjustments, 
the protective benefit of lower MCV was attenuated, so 
patients with MCV below the referent had a similar mor-
tality risk to the referent. In fully adjusted models, pa-
tients with high MCV maintained a higher mortality risk, 
with the highest risk for patients having MCV 100+ fL 
(HR 1.28, 95% CI 1.22–1.34).
In the 3 subcohorts including (i) 9,293 incident HD 
patients with baseline folate and MCV measurements, (ii) 
12,691 incident HD patients with baseline B12 and MCV 
measurements, and (iii) 36,334 incident HD patients with 
baseline KRU and MCV measurements, the MCV-mor-
tality association was similar to the main cohort in the 
case-mix plus MICS adjusted model. Further adjustment, 
separately for (i) folate, (ii) B12 and (iii) KRU, as shown 
in online supplementary Figure S3a–c, did not attenuate 
the association of higher MCV with mortality.
Time-varying models followed a similar pattern as the 
baseline MCV-mortality association. Higher MCV was 
associated with higher short-term risk of all-cause mortal-
ity across all levels of adjustment; however, lower MCV 
had no protective benefit compared to the referent (Fig. 1b, 
online suppl. Table S4). Restricted cubic splines modeling 
HRs for baseline (online suppl. Fig. S4a–c) and time-vary-
ing (online suppl. Fig. S5a–c) associations showed similar 
results and did not suggest the presence of nonlinear rela-
tionships between MCV and all-cause mortality.
Cardiovascular Mortality
Associations of MCV with cardiovascular mortality 
showed similar patterns to those in all-cause mortality 
models. In both baseline and time-varying models, the 
protective effect of lower MCV was attenuated by covari-
ate adjustments (Fig. 1c, d, online suppl. Table S5, S6). 
Patients with higher MCV maintained a higher mortality 
risk across all levels of adjustment. In baseline fully ad-
justed models, patients with MCV 100+ fL had a 27% 
higher cardiovascular mortality risk compared to the ref-
erent (HR 1.27, 95% CI 1.18–1.36). Competing risk re-
gression subhazard ratios (online suppl. Table S7) showed 
that the same patterns hold after accounting for non-car-
diovascular mortality as a competing event.
Restricted cubic splines for baseline (online suppl. Fig. 
S4d–f) and time-varying (online suppl. Fig. S5d–f) car-
diovascular mortality HRs did not suggest the presence of 
nonlinear relationships between MCV and cardiovascu-
lar mortality. 
D
ow
nl
oa
de
d 
by
: 
Un
iv.
 o
f C
al
ifo
rn
ia
 Ir
vin
e 
   
   
   
   
   
   
   
   
   
 
12
8.
20
0.
10
2.
34
 - 
10
/4
/2
01
9 
8:
48
:1
2 
PM
Dratch et al.Nephron 2019;141:188–200194
DOI: 10.1159/000495726
Table 2. Likelihood of having baseline MCV levels (≥93 fL) in 109,501 HD patients in the unadjusted, case-mix, and fully adjusted mod-
els
Unadjusted Case-mix Case-mix + MICS
OR 95% CI p value OR 95% CI p value OR 95% CI p value
Age, years (per 10) 1.36 1.35–1.37 <0.001 1.30 1.29–1.31 <0.001 1.34 1.33–1.36 <0.001
Gender, female 1.30 1.27–1.34 <0.001 1.30 1.27–1.34 <0.001 1.32 1.28–1.35 <0.001
Diabetes 0.71 0.70–0.73 <0.001 0.69 0.67–0.70 <0.001 0.72 0.70–0.74 <0.001
BMI, per 10 kg/m2 0.80 0.79–0.81 <0.001 0.87 0.86–0.89 <0.001 0.93 0.91–0.95 <0.001
Race-Ethnicity
Non-Hispanic White 1-referent 1-referent 1-referent
Asian 0.73 0.69–0.79 <0.001 0.78 0.73–0.84 <0.001 0.70 0.65–0.75 <0.001
African American 0.46 0.44–0.47 <0.001 0.55 0.54–0.57 <0.001 0.53 0.51–0.55 <0.001
Hispanic 0.61 0.59–0.63 <0.001 0.77 0.74–0.80 <0.001 0.73 0.71–0.76 <0.001
Other 0.63 0.59–0.67 <0.001 0.75 0.70–0.81 <0.001 0.72 0.67–0.77 <0.001
Insurance
Medicare 1-referent 1-referent 1-referent
Medicaid 0.65 0.62–0.68 <0.001 0.99 0.95–1.05 0.840 0.97 0.92–1.02 0.221
Other 0.76 0.74–0.78 <0.001 0.93 0.91–0.96 <0.001 0.95 0.92–0.97 <0.001
Comorbid conditions
Alcohol 1.22 0.95–1.55 0.114 1.48 1.14–1.91 0.003 1.31 1.01–1.71 0.045
ASHD 1.01 0.98–1.05 0.425 0.96 0.93–1.00 0.055 0.96 0.92–1.00 0.047
CBVD 1.05 0.96–1.15 0.253 0.97 0.88–1.07 0.527 0.98 0.89–1.08 0.671
CHF 0.93 0.91–0.95 <0.001 1.00 0.98–1.03 0.829 1.04 1.01–1.07 0.008
COPD 1.22 1.15–1.28 <0.001 1.03 0.97–1.10 0.281 1.10 1.04–1.17 0.002
Dyslipidemia 1.00 0.97–1.03 0.995 1.03 1.00–1.06 0.091 1.02 0.99–1.06 0.111
History of cancer 1.36 1.25–1.47 <0.001 1.08 0.99–1.17 0.069 1.00 0.91–1.08 0.917
Hypertension 0.95 0.93–0.97 <0.001 0.94 0.92–0.97 <0.001 0.95 0.93–0.98 <0.001
Liver disease 1.29 1.17–1.42 <0.001 1.34 1.21–1.50 <0.001 1.07 0.96–1.20 0.247
Other CD 1.08 1.04–1.11 <0.001 1.01 0.97–1.05 0.654 1.02 0.98–1.06 0.440
Access type
CVC 1-referent 1-referent 1-referent
AVF 1.01 0.98–1.04 0.616 0.96 0.92–0.99 0.012 0.93 0.90–0.97 <0.001
AVG 1.04 0.98–1.11 0.156 0.98 0.92–1.04 0.496 0.96 0.90–1.03 0.262
Other 0.90 0.61–1.32 0.589 0.97 0.65–1.44 0.874 0.95 0.63–1.42 0.785
Unknown 1.09 1.04–1.15 <0.001 1.11 1.05–1.17 <0.001 1.08 1.02–1.14 0.006
Serum laboratory values 
Albumin, per 0.5 g/dL 0.75 0.72–0.79 <0.001 0.79 0.75–0.83 <0.001 0.89 0.83–0.96 0.001
ALP, per 100 U/L 1.05 1.03–1.07 <0.001 1.11 1.09–1.13 <0.001 1.08 1.06–1.10 <0.001
B12, per 100 pg/mL 1.02 1.01–1.03 <0.001 1.02 1.01–1.03 <0.001 1.02 1.00–1.03 0.005
Bicarbonate, mEq/L 1.00 1.00–1.00 0.942 0.97 0.97–0.98 <0.001 0.97 0.97–0.98 <0.001
Calcium, mg/dL 1.12 1.10–1.14 <0.001 1.04 1.02–1.06 0.001 1.06 1.03–1.09 <0.001
Creatinine, mg/dL 0.91 0.90–0.91 <0.001 1.01 1.00–1.01 0.075 1.00 1.00–1.01 0.337
Ferritin, per 500 ng/mL 1.26 1.24–1.28 <0.001 1.22 1.20–1.24 <0.001 1.03 1.01–1.05 0.003
Folate, per 5 ng/mL 1.14 1.09–1.19 <0.001 1.05 1.00–1.10 0.057 1.06 1.00–1.11 0.036
Hemoglobin, g/dL 1.05 1.04–1.06 <0.001 1.03 1.02–1.04 <0.001 1.00 0.99–1.02 0.489
iPTH, per 250 pg/mL 0.93 0.92–0.94 <0.001 1.02 1.01–1.03 <0.001 1.02 1.01–1.04 <0.001
Iron, µg/dL 1.02 1.01–1.02 <0.001 1.02 1.02–1.02 <0.001 1.01 1.01–1.02 <0.001
Iron saturation, % 1.05 1.04–1.05 <0.001 1.05 1.05–1.05 <0.001 1.05 1.05–1.05 <0.001
KRU, mL/min 0.96 0.95–0.97 <0.001 0.96 0.95–0.97 <0.001 0.97 0.96–0.97 <0.001
LDH, per 100 U/L 1.09 1.07–1.11 <0.001 1.23 1.21–1.25 <0.001 1.18 1.15–1.20 <0.001
Lymphocyte, per 10% of WBC 0.91 0.90–0.93 <0.001 1.04 1.02–1.06 <0.001 0.98 0.96–0.99 0.009
nPCR, g/kg/d 0.90 0.85–0.95 <0.001 0.89 0.84–0.95 <0.001 0.85 0.79–0.92 <0.001
Phosphorus, mg/dL 0.89 0.88–0.90 <0.001 1.00 0.99–1.01 0.732 1.00 0.99–1.02 0.748
RDW, % 0.99 0.98–0.99 <0.001 0.96 0.95–0.96 <0.001 0.94 0.93–0.94 <0.001
Reticulocyte, % 1.00 0.97–1.04 0.751 1.02 0.99–1.06 0.177 1.01 0.98–1.05 0.471
spKt/V, per 1 increment 1.59 1.53–1.65 <0.001 1.15 1.10–1.20 <0.001 1.05 1.01–1.10 0.026
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Infectious Mortality
Patterns for infectious mortality were less consistent 
than those for all-cause or cardiovascular mortality. 
The highest group of baseline MCV was associated with 
a higher risk of infectious mortality across all levels of 
adjustment (Fig.  1e, online suppl. Table S8), with an 
18% increased risk of infectious mortality for MCV 
100+ fL compared to the referent (HR 1.18, 95% CI 
1.02–1.38) in the fully adjusted model. Associations of 
lower baseline MCV with lower infectious mortality 
risk were found but only persisted after all levels of ad-
justment for MCV groups 86–< 88 and 88–< 90. One 
group above the referent, MCV 94–< 96, also had re-
duced risk of infectious mortality. Competing risk re-
gression subHRs (online suppl. Table S10) showed that 
after accounting for noninfectious mortality as a com-
peting event, the same 3 MCV groups maintained re-
duced infectious mortality risk, and the highest group 
maintained increased risk.
In time-varying analysis (Fig. 1f, online suppl. Table 
S9), no association was observed between lower levels of 
MCV and infectious mortality, but the 2 highest MCV 
levels were associated with higher mortality. 
Restricted cubic splines for baseline (online suppl. 
Fig. S4g–i) and time-varying (online suppl. Fig. S5g–i) 
infectious mortality HRs did not suggest the presence of 
nonlinear relationships between MCV and infectious 
mortality. 
Subgroup Analyses
MCV above or equal to the median (≥93 fL) versus be-
low the median (< 93 fL) was consistently associated with 
higher all-cause, cardiovascular, and infectious mortality 
across substrata (Fig. 2, online suppl. Table S11). Asso-
ciations of higher MCV with all-cause mortality were 
stronger for patients who had diabetes or who were re-
ceiving a lower dialysis dose. Dialysis dose also similarly 
modified the association of higher MCV with cardiovas-
cular mortality. 
For all-cause mortality, significant interactions be-
tween MCV ≥93 fL and subgroups were observed for 
race, BMI, diabetes, and dialysis dose (online suppl. Ta-
ble S12). For cardiovascular mortality, interactions 
were observed for CHF and dialysis dose subgroups. No 
significant interactions were observed for infectious 
mortality.
Discussion
In a large nationally representative cohort of 109,501 
adult incident HD patients, our primary finding was a 
robust and consistent relationship between higher MCV 
with higher risk of all-cause, cardiovascular, and infec-
tious mortality in both baseline and time-varying models, 
independent of malnutrition and inflammatory status. 
Patients with higher MCV tended to be older, female, al-
coholic, non-diabetic, of non-Hispanic White race, and 
had elevated markers of poor nutrition, namely lower 
Unadjusted Case-mix Case-mix + MICS
OR 95% CI p value OR 95% CI p value OR 95% CI p value
TIBC, per 100 μg/dL 0.79 0.77–0.81 <0.001 0.82 0.80–0.84 <0.001 1.09 1.05–1.13 <0.001
WBC count, per 10 ×103/μL 1.00 0.96–1.05 0.991 0.89 0.85–0.93 <0.001 1.01 0.96–1.06 0.816
Medications
ESA use, per 10,000 U 1.00 0.99–1.01 0.543 1.00 0.99–1.01 0.919 1.00 0.99–1.01 0.625
IV iron, per 500 mg 0.91 0.91–0.92 <0.001 0.92 0.91–0.93 <0.001 1.00 0.99–1.01 0.616
Please note: In logistic regression analyses, models were restricted to patients that had the risk factor of interest, and were adjusted 
for all other components in the multilevel adjustment minus the exposure.
BMI, body mass index; ASHD, arteriosclerotic heart disease; CBVD, cerebrovascular disease; CHF, congestive heart failure ; COPD, 
chronic obstructive pulmonary disease; Other CD, other cardiac disease; CVC, central venous catheters; AVF, arteriovenous fistula; 
AVG, arteriovenous graft; ALP, alkaline phosphatase; B12, vitamin B12; iPTH, intact parathyroid hormone; KRU, residual renal urea 
clearance; LDH, lactic acid dehydrogenase; nPCR, normalized protein catabolic rate; RDW, red cell distribution width; spKt/V, single-
pooled Kt/V; TIBC, total iron binding capacity; WBC, white blood cell count, ESA, erythropoiesis stimulating agent; IV, intravenous. 
MCV, mean corpuscular volume.
Table 2. (continued)
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Unadjusted
Case-mix
Case-mix and MICS
MCV, fL
<86
86–
<88
88–
<90
90–
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92–
<94
94–
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96–
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98–
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0
100
+
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1.8
2.0
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2.4
a
Unadjusted
Case-mix
Case-mix and MICS
MCV, fL
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c
Unadjusted
Case-mix
Case-mix and MICS
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e
Unadjusted
Case-mix
Case-mix and MICS
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86–
<88
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d
Unadjusted
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Case-mix and MICS
MCV, fL
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f
1
(For legend see next page.)
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baseline albumin, nPCR, phosphorus concentrations, se-
rum creatinine, and BMI. Furthermore, KRU was lower 
in patients with higher MCV levels. 
Macrocytosis may be a surrogate for an end-stage mal-
nutrition-related poor health condition. While hypoalbu-
minemia is associated with malnutrition and inflamma-
tion [15], lower nPCR and phosphorus may be indicative 
of low protein intake [16, 17]. Lower serum creatinine 
correlates with a lower muscle mass [18, 19] in dialysis 
patients and declining residual kidney function may be a 
All-cause mortality HR for MCV
≥93 (vs. <93)
Folate <9.6
Folate ≥9.6
B12 <620
B12 ≥620
ESA use <5,000
ESA use ≥5,000
IV iron = 0
IV iron >0–≤1,000
IV iron >1,000
TIBC <200
TIBC ≥200
Iron saturation <22%
Iron saturation ≥22%
Iron <50
Iron ≥50
Ferritin <800
Ferritin ≥800
RDW <15.5
RDW ≥15.5
Hemoglobin <12
Hemoglobin ≥12
Lymphocyte <21
Lymphocyte ≥21
White blood cell <11
White blood cell ≥11
nPCR <0.79 
nPCR ≥0.79
Albumin <4
Albumin ≥4
spKt/V <1.2
spKt/V ≥1.2
No CHF
CHF
No diabetes
Diabetes
BMI <25
BMI ≥25
Male
Female
Hispanic
Non-Hispanic White
African American
Age ≥65
Age <65
All patients
0.7 0.8 0.9 1.0 1.1 1.3 1.5 2.0
Cardiovascular mortality HR for MCV
≥93 (vs. <93)
0.7 0.8 0.9 1.0 1.1 1.3 1.5 2.0
Infectious mortality HR for MCV
≥93 (vs. <93)
0.7 0.8 0.9 1.0 1.1 1.3 1.5 2.0
a b c
Fig. 2. Subgroup analysis of fully adjusted (case-mix plus MICS) (a) 
all-cause, (b) cardiovascular, and (c) infectious mortality HRs (and 
95% CI error bars) of high MCV (MCV ≥93 fL) vs. low MCV (MCV 
< 93 fL). HR, hazard ratio; MCV, mean corpuscular volume; BMI, 
body mass index; CHF, congestive heart failure; spKt/V, single-
pooled Kt/V; nPCR, normalized protein catabolic rate; RDW, red 
cell distribution width; TIBC, total iron binding capacity; IV, intra-
venous; ESA, erythropoiesis stimulating agent; B12, vitamin B12.
Fig. 1. Baseline (a) and time-varying (b) all-cause, baseline (c) and time-varying (d) cardiovascular, baseline (e) and time-varying (f) 
infectious  mortality HRs (and 95% CI error bars) by MCV levels across 3 levels of multivariable adjustment. HR, hazard ratio; MCV, 
mean corpuscular volume; MICS, malnutrition-inflammation complex syndrome.
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factor in malnutrition and inflammation [20]. In fact, 
protein-energy wasting and inflammation are commonly 
found in dialysis patients [21, 22]. It has been postulated 
that malnutrition could lead to a change in osmotic pres-
sure contributing to erythrocyte swelling and a higher 
MCV [11]. Malnutrition may partially confound the re-
lationship between MCV and mortality, but the associa-
tion of higher MCV with mortality persisted after MICS 
adjustment. Additionally, adjusting for residual kidney 
function in a subset of patients did not remove the asso-
ciation. Therefore, we conclude that malnutrition alone 
cannot fully explain the association between high MCV 
and mortality. 
Associations between high MCV and B12 and folic 
acid deficiencies have been well established [6, 23, 24]. 
Soohoo et al. [25] studied B12- and folate-mortality as-
sociations using the same database as was used in this 
study. They concluded that higher B12 (B12 ≥550 pg/
mL) and lower folate (folate < 6.2 ng/mL) were associ-
ated with higher all-cause mortality. However, in addi-
tional analysis including only a subset of our analytical 
cohort, we found that high MCV was associated with 
higher all-cause mortality even after adjusting for folate 
and B12. 
Another potential source of residual confounding is 
the impact of ESA therapy. ESA can lead to an increase in 
the reticulocyte population [12], which can thereby lead 
to increased MCV. A previous study described an asso-
ciation between MCV > 102 fL and higher darbepoetin to 
hemoglobin ratio in maintenance HD patients [12], while 
in another study the MCV-mortality association was not 
significantly altered after adjustment for medication ther-
apy including ESA [11]. Even though we adjusted for ESA 
in our baseline and time-varying models, one can argue 
that this may not account for the time to effect of ESA, 
since the ESA dose and MCV levels were measured in the 
same patient quarter. However, the trajectory model of 
mean MCV over 20 patient quarters stratified by baseline 
MCV group was not altered by ESA and IV iron adjust-
ment. 
Another potential explanation for the association be-
tween elevated MCV and mortality may be linked to the 
molecular aging process. In our study, older age was as-
sociated with higher MCV, which is consistent with other 
studies [26]. Relationships of leukocyte telomere length 
with heart disease, cancer, infections, and overall mortal-
ity have been previously described [27–29]. With every 
division, DNA polymerase cannot fully replicate the 3’ 
end of a DNA strand; thus the telomere length becomes 
shorter and eventually reaches a critical length that can 
lead to cell death [27]. Kozlitina and Garcia [30] mea-
sured the length of genomic DNA isolated from circulat-
ing leukocytes in 3,157 subjects that were enrolled in the 
Dallas Heart Study 2. Using a multiple regression model 
they found that shorter telomeres were significantly as-
sociated with larger MCV. Furthermore, shorter telo-
meres may be related to infectious diseases [31, 32]. In our 
analysis, associations of higher MCV with mortality were 
only slightly attenuated after adjustment for age; howev-
er, we were unable to account for differing telomere 
length.
Furthermore, RBC metabolism and homeostasis 
strongly affect the antioxidant properties of the whole 
body, and alteration of the erythrocyte membrane may 
result in a reduction of its antioxidant capacity [9, 33, 
34]. Solak et al. [34] showed that MCV was associated 
with endothelial dysfunction, independent of inflam-
mation, suggesting that the harmful impact of higher 
MCV level on endothelial function may be a conse-
quence of the compromised antioxidant potential of 
macrocytic erythrocytes. Interestingly, the overproduc-
tion of reactive oxygen species may play a causative role 
in the development and progression of cardiovascular 
disease [9].
We were unable to account for these factors in our co-
hort analysis, and thus recommend future studies with 
the ability to capture data on oxidative stress to explore 
this possibility. The precise mechanisms by which MCV 
and mortality are related are yet to be determined.
Strengths of this study include the large sample size, 
thorough adjustment for common markers of malnutri-
tion and inflammation, and refined categories of MCV 
that allowed us to examine non-linear relationships. 
Limitations include the possibility of residual confound-
ing and our inability to infer causality due to the retro-
spective observational study design. We also lacked data 
on certain confounders, namely measures of C-reactive 
protein, reactive oxygen species, other inflammatory 
markers, the number of blood transfusions, and medica-
tions known to induce macrocytosis. Moreover, we can-
not provide any information on pre-ESRD treatment 
such as ESA dose or IV iron, which might confound the 
baseline MCV-mortality association. For our baseline 
models, monthly cumulative IV iron and weekly median 
ESA use were documented after dialysis initiation over a 
90-day period, during the same time frame as the base-
line MCV measurement. 
In conclusion, in a large national cohort of incident 
HD patients in the United States, higher MCV levels were 
associated with higher risk of all-cause, cardiovascular, 
D
ow
nl
oa
de
d 
by
: 
Un
iv.
 o
f C
al
ifo
rn
ia
 Ir
vin
e 
   
   
   
   
   
   
   
   
   
 
12
8.
20
0.
10
2.
34
 - 
10
/4
/2
01
9 
8:
48
:1
2 
PM
MCV and Mortality 199Nephron 2019;141:188–200
DOI: 10.1159/000495726
and infectious mortality. Further studies are needed to 
understand the pathophysiology underlying this relation-
ship, and the potential advanced utility of evaluating 
MCV level in clinical practice.
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